Bullous pemphigoid in a patient treated with nivolumab
- 24 July 2019
- journal article
- letter
- Published by Hindawi Limited in Dermatologic Therapy
- Vol. 32 (5) , e13030
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Anti-programmed cell death-1 therapy-associated bullous disorders: a systematic review of the literatureMelanoma Research, 2018
- Timing of Onset of Adverse Cutaneous Reactions Associated With Programmed Cell Death Protein 1 Inhibitor TherapyJAMA Dermatology, 2018
- Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic MelanomaJournal of Clinical Oncology, 2018
- Gray‐bluish cutaneous pigmentation and ice‐pick scars induced by vandetanib therapyInternational Journal of Dermatology, 2018
- Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III TrialsJournal of Clinical Oncology, 2017
- Histopathologic Features of Colitis Due to Immunotherapy With Anti-PD-1 AntibodiesAmerican Journal of Surgical Pathology, 2017
- A molecular and preclinical comparison of the PD-1–targeted T-cell checkpoint inhibitors nivolumab and pembrolizumabSeminars in Oncology, 2017
- Diverse types of dermatologic toxicities from immune checkpoint blockade therapyJournal of Cutaneous Pathology, 2016
- Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodiesCurrent Opinion in Oncology, 2016
- Immune-related adverse events with immune checkpoint blockade: a comprehensive reviewEuropean Journal of Cancer, 2016